Incannex Healthcare rises as anxiety treatment meets mid-stage trial goal

Incannex Healthcare

26/08/2025 13:46

** U.S.-listed shares of drug developer Incannex Healthcare IXHL.O  rise 14.4% to 85 cents in premarket trading

** Australia-based company says its experimental drug to treat anxiety disorder met the main goal of a mid-stage study

** Says PSX-001 helped reduce symptoms of the disorder when measured on a disease severity scale

     ** PSX-001 demonstrated a reduction in anxiety, improved mood, enhanced quality of life and better day-to-day functioning- IXHL

** The treatment was well tolerated with no serious adverse events reported, co says

** Co says it is exploring strategic ties to accelerate development and broaden global access to PSX-001

** Up to last close, stock down 65.1% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com))